Hepatitis C & Viral Hepatitis Support Protocol
Hepatitis C & Viral Hepatitis Support Protocol framework focused on consistent execution, practical monitoring, and safer progression.
A supportive protocol for patients with chronic viral hepatitis (HCV, HBV) combining thymic immune restoration, direct antiviral peptides, and hepatoprotective compounds to enhance viral clearance, reduce hepatic fibrosis, and improve treatment outcomes alongside standard antiviral therapy.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Hepatitis C & Viral Hepatitis Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Thymosin Alpha-1: induction x28 days then 2x/week ongoing until sustained virological response. Others continuous while on antiviral therapy.
Target Audience
Adults with chronic HCV or HBV on or completing antiviral therapy; use under hepatology supervision
| Compound | Dose | Frequency |
|---|---|---|
| Thymosin Alpha-1 Thymosin Alpha-1: most clinically validated peptide for viral hepatitis; approved HCV/HBV adjuvant; restores CD4+/CD8+ T cell antiviral response; increases SVR rates | 1.6 mg | Twice weekly SC (maintenance) or daily x28 days (intensive) |
| BPC-157 BPC-157: hepatoprotective via NO pathway; reduces hepatic NF-kB activation; prevents progression of inflammation to fibrosis; cytoprotective for hepatocytes | 250 mcg | Twice daily SC |
| KPV KPV: alpha-MSH anti-inflammatory tripeptide; suppresses TLR4/NF-kB in Kupffer cells; reduces gut-liver axis inflammation that drives fibrosis progression | 500 mcg | Daily SC |
| LL-37 LL-37: direct antiviral activity against HCV envelope protein; enhances NK cell-mediated hepatic viral surveillance; reduces secondary bacterial infections | 200-500 mcg | Daily SC |
| NAD+ NAD+: corrects HCV-induced mitochondrial dysfunction; SIRT1 activation reduces hepatic steatosis; supports sirtuin-dependent antiviral immune responses | 500 mg NMN | Once daily oral |
| Thymalin Thymalin: thymic polypeptide; restores nave T cell production from thymus to replace exhausted antiviral T cell clones; complements Thymosin Alpha-1 | 1-5 mg | Daily SC for 10-day cycles, 2x/year |
Free Peptide Guide
Hepatitis C & Viral Hepatitis Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned Thymosin Alpha-1 timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Hepatitis C & Viral Hepatitis Support Protocol run before reassessment?
A common window is Thymosin Alpha-1: induction x28 days then 2x/week ongoing until sustained virological response. Others continuous while on antiviral therapy., with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with Thymosin Alpha-1 + BPC-157 execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
Thymosin Alpha-1 has the strongest evidence base of any peptide in viral hepatitis — it was approved as an HBV and HCV adjuvant in multiple countries and demonstrated enhanced sustained virological response (SVR) when combined with interferon and ribavirin. It restores exhausted CD4+ and CD8+ T cell responses that are the primary mechanism of viral hepatic clearance. BPC-157 protects hepatocytes from oxidative stress and inflammatory injury, reduces hepatic NF-κB activation, and prevents fibrotic progression toward cirrhosis. KPV suppresses hepatic toll-like receptor-mediated inflammation driven by gut-derived LPS. LL-37 demonstrates direct antiviral activity against HCV via envelope protein disruption and enhances NK cell hepatic surveillance. NAD+ corrects the mitochondrial dysfunction and sirtuin depletion central to hepatic steatosis in HCV. Thymalin complements Thymosin Alpha-1 by restoring thymic output of fresh nave T cells.
Clinical Research
No clinical references were provided for this stack yet.
More Immune Support Stacks
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol
An adjunctive protocol for individuals with ankylosing spondylitis and axial spondyloarthropathy, targeting the IL-17/IL-23-driven enthesitis, progressive syndesmophyte formation, and the TNF-driven inflammatory cascade that cause irreversible spinal fusion.
Ankylosing Spondylitis & Axial Spondyloarthropathy Protocol
Anti-inflammatory and joint-protective peptide protocol for ankylosing spondylitis targeting spinal inflammation, syndesmophyte prevention, and preservation of spinal mobility.
Crohn's Disease & IBD Management Protocol
Peptide-based protocol targeting intestinal inflammation, barrier repair, and mucosal immune regulation for Crohn's disease and ulcerative colitis management.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Hepatitis C & Viral Hepatitis Support Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.